Current Status and Prospects of Radiopharmaceuticals for Diagnosis
YOU Lin-yi1;GUO Zhi-de1,2;ZHANG Xian-zhong1
1.Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, Xiamen 361102, China;2.Department of Isotope, China Institute of Atomic Energy, Beijing 102413, China
Single-photon emission computed tomography (SPECT) and positron emission tomography (PET) technologies based on radiopharmaceuticals have become very effective diagnostic tools, which can reflect the functional and metabolic processes of living bodies at the molecular level. Radiopharmaceutical research and development provide a strong guarantee for molecular imaging and nuclear medicine development. Continuous research in radiopharmaceuticals by Chinese researchers have laid a solid foundation. This paper introduces the latest research progress in the field of radiopharmaceuticals for diagnosis in China in recent years, and prospects for the development of radiopharmaceuticals in China in the near future. The suggestions were proposed to strengthen the accelerator radionuclide development, radiopharmaceutical research, personnel training and other aspects of investment or research proposals in order to achieve this field to achieve more long-term development, better for human health services.